Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Identifying and treating patients with psychosis who are positive to anti-neuronal antibodies (NHMRC funded multisite study)

Projekt: Typer af projekterProjekt

  • Scott, James, The University of Queensland, Australien (Projektleder, faglig)
  • Benros, Michael Eriksen (Projektleder, faglig)
  • O'Donoghue, Brian, Orygen, The National Centre of Excellence in Youth Mental Health, Australien (Projektdeltager)
  • Lennox, Belinda, University of Oxford, Storbritannien (Projektleder, faglig)
Vis graf over relationer
Intro: Psychosis is a heterogeneous disorder with a highly variable prognosis where treatment refractory and relapsing courses with persistent disability are all too common. There are a growing number of case reports of patients with psychosis who have anti-neuronal antibodies (ANAb).
Metoder: The study will screen 1200 individuals with new onset psychosis positive to anti-neuronal antibodies in blood, which based on treatment decision are randomized to receive Immunotherapy. Outcome: compare the 12 month functional outcomes of patients who receive immunotherapy early after onset of illness with those who receive later or no immunotherapy.
Resultater (forventede): This study aims to provide guidance as to which patients with psychosis should be tested for ANAb by prospectively validating proposed higher
risk clinical criteria for psychosis associated with NSAbs in a large patient population (n=1200).
Diskussion/impact (forventet): This study will provide critical information to enable the most efficient use of health resources whilst ensuring patients with psychosis who are positive for ANAb presenting to mental health services are detected early so as to prevent delays in diagnosis of autoimmune illness and provision of treatment.
StatusIgangværende
Periode01/01/201931/12/2022

    Forskningsområder

  • Sundhedsvidenskab - Neurocognitive/Organic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Biomarkers, Cognition, Neuroimaging, Neurophysiology, Pharmacology, Physical Treatments, Randomized Controlled Clinical Trial

ID: 61896393